PD-L1 (CPS) >= 1

About

Biomarker Type: Protein expression

Present: True

Marker: PD-L1

Unit: Combined Positive Score (CPS)

Equality: >=

Value: 1


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
EMA (1) FDA (2) HSE (2) PD-L1 (CPS) >= 1 Head and Neck Squamous Cell Carcinoma Pembrolizumab
EMA (1) FDA (1) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab, Trastuzumab
FDA (1) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Pembrolizumab, Trastuzumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Adenocarcinoma Cisplatin, Paclitaxel, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Squamous Cell Carcinoma Cisplatin, Paclitaxel, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Adenocarcinoma Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Squamous Cell Carcinoma Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab
EMA (1) FDA (1) HSE (1) PD-L1 (CPS) >= 1 Cervical Adenocarcinoma Carboplatin, Paclitaxel, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Squamous Cell Carcinoma Carboplatin, Paclitaxel, Pembrolizumab
EMA (1) FDA (1) HSE (1) PD-L1 (CPS) >= 1 Cervical Adenocarcinoma Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Squamous Cell Carcinoma Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab
FDA (1) HSE (2) PD-L1 (CPS) >= 1 Cervical Adenocarcinoma Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Squamous Cell Carcinoma Pembrolizumab
EMA (1) HSE (1) PD-L1 (CPS) >= 1 Head and Neck Squamous Cell Carcinoma Carboplatin, Fluorouracil, Pembrolizumab
EMA (1) HSE (1) PD-L1 (CPS) >= 1 Head and Neck Squamous Cell Carcinoma Cisplatin, Fluorouracil, Pembrolizumab
EMA (1) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Carboplatin, Fluorouracil, Pembrolizumab, Trastuzumab
EMA (1) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab
EMA (1) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Carboplatin, Fluorouracil, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Cisplatin, Fluorouracil, Tislelizumab
FDA (1) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Capecitabine, Cisplatin, Tislelizumab
FDA (1) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Fluorouracil, Oxaliplatin, Tislelizumab
FDA (1) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Capecitabine, Oxaliplatin, Tislelizumab
FDA (1) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Cisplatin, Paclitaxel, Tislelizumab
FDA (1) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Oxaliplatin, Paclitaxel, Tislelizumab
FDA (1) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Tislelizumab
FDA (1) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Tislelizumab